1	Full Title
2	Sex Differences in Management, Time to Intervention, and In-Hospital Mortality of Acute
3 4	Myocardial Infarction and Non-Myocardial Infarction Related Cardiogenic Shock
5	Authors
6	Anushka Desai, BS ¹ ; Rohan Rani, BS ¹ ; Anum Minhas, MD MHS ² ; Faisal Rahman BM BCh ²
7	
8	1. Georgetown University School of Medicine
9	2. Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore,
10	Maryland, USA.
11	
12	Short Title
13	Sex Differences in Cardiogenic Shock
14	
15	Corresponding Author Information
16	Anushka Desai
17	ad1551@georgetown.edu
18 19	3603 T Street NW Washington D.C., 20007
20	Total Word Count – 2,218
21	
22	Acknowledgements
23	None
24	
25	Sources of Funding
26	Dr. Minhas is supported by NIH/NHLBI K23HL171886.
27	
28	Disclosures
29 30	None
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	

41 Abstract

42 <u>Background</u>

43 Limited data are available on sex differences in the time to treatment of cardiogenic shock (CS)
44 with and without acute myocardial infarction (AMI).

- 45
- 46 <u>Methods</u>

47 For this retrospective cohort study, we used nationally representative hospital survey data from

the National Inpatient Sample (years 2016-2021) to assess sex differences in interventions, time

49 to treatment (within versus after 24 hours of admission), and in-hospital mortality for AMI-CS

and non-AMI-CS, adjusting for age, race, income, insurance, comorbidities, and prior cardiac

- 51 interventions.
- 52
- 53 <u>Results</u>

54 We identified 1,052,360 weighted CS hospitalizations (60% non-AMI-CS; 40% AMI-CS).

55 Women with CS had significantly lower rates of all interventions. For AMI-CS, women had a

56 higher likelihood of in-hospital mortality after: revascularization (adjusted odds ratio (aOR) 1.15

57 [95% CI 1.09-1.22]), mechanical circulatory support (MCS) (1.15 [1.08-1.22]), right heart

58 catheterization (RHC) (1.10 [1.02-1.19]) (all p<0.001). Similar trends were found for the non-

59 AMI-CS group. Women with AMI-CS were less likely to receive early (within 24 hours of

60 admission) revascularization (0.93 [0.89-0.96]), MCS (0.76 [0.73-0.80]), or RHC (0.89 [0.84-

61 0.95]) than men; women with non-AMI-CS were less likely to receive early revascularization

62 (0.78 [0.73-0.84]), IABP (0.85 [0.78-0.94]), pLVAD (0.88 [0.77-0.99]) or RHC (0.83 [0.79-

63 0.88]) than men (all p<0.001). For both types of CS, in-hospital mortality was not significantly

64 different between men and women receiving early ECMO, pLVAD, or PCI.

65

66 <u>Conclusions</u>

67 Sex disparities in the frequency of treatment of CS persist on a national scale, with women being

68 more likely to die following treatment and less likely to receive early treatment. However, when

69 comparing patients who received early treatment, in-hospital mortality does not differ

significantly when men and women are treated equally within 24 hours of admission. Early

71 intervention if clinically indicated could mitigate sex-based differences in CS outcomes and

should be made a priority in the management of CS.

- 73
- 74
- 75
- 76 77

78

70

79

81 <u>Clinical Perspective</u>

- 82 What is new?
- Women have increased in-hospital mortality with cardiogenic shock and have lower odds
 of early intervention (within 24 hours of admission) compared to men.
- When men and women with cardiogenic shock are treated equally in terms of early intervention within 24 hours of admission, sex differences in in-hospital mortality disappear.
- 88

89 What are the clinical implications?

- 90 Sex-based disparities are present in the utilization of treatment and time to intervention
 91 for patients with cardiogenic shock.
- Early recognition and intervention for cardiogenic shock among women should be considered to improve clinical outcomes.
- 94
- 95

96 Abbreviations

- 97 CS Cardiogenic Shock
- 98 AKI Acute Kidney Injury
- 99 AMI Acute Myocardial Infarction
- 100 MCS Mechanical Circulatory Support
- 101 RHC Right Heart Catheterization
- 102 HCUP Healthcare Cost and Utilization Project
- 103 NIS National Inpatient Sample
- 104 PCI Percutaneous Intervention
- 105 CABG Coronary Artery Bypass Graft
- 106 IABP Intra-Aortic Balloon Pump
- 107 pLVAD Percutaneous Left Ventricular Assist Device
- 108 LVAD Left Ventricular Assist Device
- 109 ECMO Extracorporeal Membrane Oxygenation
- 110 aOR Adjusted Odds Ratio
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120

121 Introduction

122 Cardiogenic shock (CS) is defined as a state of decreased circulation causing hypoxia and end-

123 organ hypoperfusion. It is frequently precipitated by acute myocardial infarction (AMI).¹ Despite

advancements in medical interventions over the past 20 years, CS remains associated with high

125 mortality ranging between 30-50%.²⁻⁵ There exist marked sex disparities in mortality associated

126 with CS in the United States.⁶⁻⁸ Current literature suggests insufficient recognition of symptoms

- 127 in women, faltering guideline-directed medical therapy during the first 24 hours, and inadequate
- 128 utilization of mechanical circulatory support (MCS) devices as underlying reasons for the
- 129 observed mortality difference.⁹
- 130

131 In all patients, rapid deterioration following CS necessitates timely intervention to improve

132 clinical outcomes.^{10,11} Recently, the DanGer Shock trial has driven the point of early aggressive

treatment of AMI-CS, finding that prompt routine use of percutaneous left ventricular assist

134 devices (pLVAD) decreases the risk of all-cause mortality.¹² This is especially pertinent when

135 considering a recent cohort study that found women to be less likely to receive pLVAD when

136 hospitalized for CS.¹³ Given that earlier intervention can result in improved clinical outcomes,

137 we aimed to investigate whether differences in timely intervention were associated with higher

138 mortality among women compared to men.

- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146 147

- 149
- 150
- 151
- 152
- 153
- 154 155
- 156
- 157
- 158
- 159
- 160

161 Methods

- 162 <u>Study Data</u>
- 163 Data was obtained from the Healthcare Cost and Utilization Project (HCUP) National Inpatient
- 164 Sample (NIS) database, which is sponsored by the Agency of Healthcare Research and Quality.
- 165 The NIS is the largest publicly available all-payer administrative database in the United States. It
- 166 contains hospitalization data from a stratified 20% sample of over 1,000 hospitals across the
- 167 nation participating in the HCUP, and, when weighted, can be used to estimate nationwide trends
- 168 and incidence.
- 169

170 <u>Study Population & Outcomes</u>

- 171 The database was queried for adult patients (≥ 18 years) admitted with CS from 2016 to 2021,
- using the International Classification of Disease 10th Revision Clinical Modification Codes of
- 173 R57.0. We categorized these hospitalizations by the presence of AMI on admission into two
- 174 cohorts: non-AMI CS and AMI-CS. Hospitalizations missing mortality or sex data were
- 175 excluded. Study flowchart is included in **Figure S1**.
- 176
- 177 Baseline demographics, comorbidities, and prior interventions were identified with ICD-10-CM
- 178 codes. These characteristics included census-defined age group, race/ethnicity, quartile of
- 179 median household income, insurance, hospital type, hospital teaching status, obesity,
- 180 dyslipidemia, diabetes mellitus, hypertension, tobacco use, peripheral vascular disease, chronic
- 181 heart failure, chronic kidney disease, chronic liver disease, valvular heart disease, coronary artery
- 182 disease, stroke, prior percutaneous intervention (PCI), and prior coronary artery bypass graft
- 183 (CABG).
- 184
- 185 The procedural outcomes analyzed were revascularization (Percutaneous Coronary Intervention
- 186 [PCI] and Coronary Artery Bypass Graft [CABG]), MCS (Intra-aortic Balloon Pump [IABP],
- 187 Percutaneous Left Ventricular Assist Device [pLVAD], Extracorporeal Membrane Oxygenation
- 188 [ECMO]), RHC, and advanced heart failure therapies (LVAD and heart transplant). The clinical
- 189 outcomes studied included in-hospital mortality, use of invasive mechanical ventilation, major
- 190 bleeding, acute kidney injury, and stroke. **Table S1** includes a complete list of all ICD-10
- 191 diagnosis and procedure codes used.
- 192
- 193 <u>Statistical Analysis</u>
- All data represent weighted national estimates, which were done using HOSP_NIS as a
- 195 clustering variable and NIS_STRATUM to account for different strata, as recommended by the
- 196 AHRQ methods.¹⁴ Differences in baseline data, procedural outcomes, and clinical outcomes
- 197 between the type of CS and sex were compared using Pearson's χ^2 test for categorical variables
- and the Mann-Whitney test for continuous variables.
- 199

Multivariable logistic regressions that accounted for survey weighting were used to assess sex differences in use of intervention at any point during hospitalization, early treatment (within 24 hours of admission), and adverse clinical outcomes for both AMI and non-AMI CS, adjusting for all baseline demographics, comorbidities, and prior interventions. Further subgroup analyses were performed to assess sex differences in in-hospital mortality associated with receiving early versus late intervention. Statistical significance was defined with a type I error of < 0.05. All analyses were performed using STATA Statistical Software version 18.0.

240 **Results**

- 241 <u>Baseline Characteristics</u>
- Our study included 1,052,360 weighted hospitalizations with CS between 2016 and 2021. As
- seen in **Table 1**, both non-AMI-CS and AMI-CS had a higher incidence in men compared to
- 244 women (non-AMI-CS 61.8% vs 38.1%; AMI-CS 63.6% vs 36.3%; p<0.001). Women were more
- 245 likely to be older with CS. Women with CS, compared to men, had higher frequencies of obesity,
- valvular heart disease, and stroke, and lower frequencies of coronary artery disease and prior PCI
- 247 or CABG (p<0.001).
- 248

249 Procedural and Clinical Outcomes

- 250 For both types of CS, women had significantly lower frequencies of almost every type of
- 251 intervention compared to men (p<0.001), the only exception being heart transplant for AMI-CS
- 252 (Table 2). Women had higher frequencies of in-hospital mortality, use of mechanical ventilation,
- and stroke during hospitalization, and lower frequencies of major bleeding events and acute
- kidney injury compared to men. Hospital length of stay and total charges were significantly
- lower for women than men. These trends were observed after adjusting for baseline
- characteristics and comorbidities as well (Tables S2-3).
- 257

258 Outcomes after Intervention for AMI-CS

- 259 Women with AMI-CS undergoing revascularization had higher mortality (aOR: 1.15; 95% CI:
- 260 1.09-1.22; p<0.001), were more likely to require mechanical ventilation (aOR: 1.07; 95% CI:
- 261 1.02-1.12; p=0.003), and have a stroke (aOR: 1.62; 95% CI: 1.12-2.35; p<0.001) during their
- hospitalization compared to men (**Table 3**). When MCS was utilized, women were more likely to
- have higher mortality (adjusted odds ratio (aOR): 1.15; 95% CI: 1.08-1.22; p<0.001), be placed
- on mechanical ventilation (aOR: 1.12; 95% CI: 1.06-1.19; p<0.001), or have a major bleeding
- event (aOR: 1.08; 95% CI: 1.01-1.15; p=0.01) during their hospitalization than men. After RHC,
 women were more likely to die (aOR: 1.10; 95% CI: 1.02-1.19; p<0.001) or be placed on
- 267 wohen were more neerly to the (aOR: 1.10, 95% CI: 1.02-1.19, p<0.001) of be placed on 267 mechanical ventilation (aOR: 1.12; 95% CI: 1.04-1.21; p=0.002) during their hospitalization than
- 268 men. No significant differences in adverse clinical outcomes between men and women receiving
- advanced heart failure therapy were noted.
- 270
- 271 <u>Outcomes after Intervention for non-AMI-CS</u>
- Following revascularization, women with non-AMI-CS were more likely to die (aOR: 1.38; 95%
- 273 CI: 1.23-1.56; p<0.001) and be placed on mechanical ventilation (aOR: 1.11; 95% CI: 1.00-1.24;
- p=0.050) during their hospitalization than men (**Table 4**). Women receiving MCS were more
- likely to die (aOR: 1.31; 95% CI: 1.21-1.43; p<0.001), be placed on mechanical ventilation
- 276 (aOR: 1.28; 95% CI: 1.18-1.40; p<0.001), or have a major bleeding event (aOR: 1.10; 95% CI:
- 277 1.02-1.18; p=0.012) during their hospitalization than men. The same was true after RHC for in-
- hospital mortality (aOR: 1.32; 95% CI: 1.22-1.43; p<0.001) and mechanical ventilation usage

279 (aOR: 1.27; 95% CI: 1.17-1.36; p<0.001). No significant differences in adverse clinical

- outcomes between men and women receiving advanced heart failure therapy were noted.
- 282 Incidence and Mortality Following Early Intervention
- 283 For both types of shock, women had a lower frequency of receiving CABG, IABP, pLVAD, and
- 284 RHC within 24 hours of admission compared to men (Figure 1). Women with AMI-CS
- additionally had lower frequencies of undergoing placement on ECMO and PCI within 24 hours.
- 286 This was similarly reflected after adjusting for covariates, with women with AMI-CS being less
- 287 likely to receive any type of revascularization, MCS, or RHC than men, and women with non-
- AMI-CS being less likely to receive any type of revascularization, IABP, pLVAD, RHC, or
- 289 LVAD than men (**Figure 2**). In-hospital mortality did not change significantly between men and
- women with AMI-CS undergoing early revascularization, pLVAD, ECMO, or RHC (**Figure 3**).
- 291 For those with non-AMI-CS, in-hospital mortality did not change significantly when treated
- early with PCI, pLVAD, ECMO, or RHC (**Figure 3**). For AMI-CS, women receiving early
- interventions of any revascularization or within 24 hours were far less likely to die during their
- hospitalization than women who received intervention after 24 hours or not at all; meanwhile, for
- non-AMI-CS, this was the case for women receiving early CABG, IABP, or RHC (**Table 5**).
- 296
- 297 298
- 299
- 300
- 301
- 302
- 303
- 304

- 306
- 307 308
- 309
- 310
- 311
- 312
- 313
- 314
- 315
- 316
- 317
- 318

319 Discussion

320 To our knowledge, this study is the first to examine sex differences in management and

- 321 outcomes of patients with AMI-CS and non-AMI-CS utilizing time to intervention. We found
- that (1) women with either type of CS are less likely to undergo interventions during
- 323 hospitalization than men; (2) even after receiving intervention, in-hospital mortality, mechanical
- ventilation, and major bleeding are more likely to occur in women with CS than men; (3) among
- 325 patients undergoing intervention, women are less likely to have an intervention performed within
- 326 24 hours of admission; (4) and with early intervention, there was no difference in mortality
- among women and men.
- 328

329 Previous studies have demonstrated that women are less likely to receive MCS therapies in CS and experience a 10% higher mortality risk.¹¹ Not only did we confirm these findings, but we 330 also found that women had significantly lower frequencies of nearly all types of interventions 331 332 compared to men and were less likely to receive these interventions early. This was associated 333 with higher frequencies of in-hospital mortality, invasive mechanical ventilation, and stroke during hospitalization. Prior analyses of NIS data from 2006 to 2015 found that, for AMI-CS, 334 women were more likely to die during their hospitalization than men (aOR 1.11, 95% CI: 1.06-335 1.16 p < 0.001).¹⁵ Despite significant recognition of sex disparities in management and mortality 336 337 rates of many conditions, our analysis shows that the situation has yet to improve significantly in 338 the subsequent decade for CS.

339

340 The results of this study suggest that ongoing sex disparities in mortality and outcomes of CS 341 may be related to time to intervention. When women and men are similarly treated with early 342 intervention for CS, outcomes are comparable. Additionally, women with CS undergoing any 343 revascularization, IABP, or RHC within 24 hours of admission were far less likely to die during their hospitalization than women who received intervention after 24 hours or not at all. Both of 344 345 these findings point to late intervention as a plausible explanation for the observed outcome 346 differences and demonstrate the tangible impact of timely intervention in narrowing the sex gap 347 in clinical outcomes for CS.

348

349 Research has extensively explored the elevated mortality in women with CS, especially within the context of AMI. One hypothesis posits that women in low-output states are less likely to be 350 351 recognized by providers as experiencing CS. This is supported by studies on sex-based differences in time to treatment for AMI, showing delays at every stage of care (from symptom 352 onset to EMS call, EMS to hospital admission, and hospital admission to reperfusion therapy).¹⁶ 353 Early intervention has been shown to be crucial in the treatment of CS, lending to better post-354 procedure outcomes and lower rates of in- and out-hospital mortality.^{17,18} Reasons for this 355 include improved perfusion resulting in the prevention of irreversible ischemic damage and 356 357 pathologic cardiac remodeling.

Clinically, improving recognition of low-output states in women can lead to decreased time to 359 360 treatment for CS. When looking at the temporal trends of women undergoing AMI, female sex has been associated with a greater time to reperfusion even when adjusting for all baseline 361 characteristics and types of reperfusion therapy used.^{19,20} It is equally important to note that 362 when performing a clinical assessment of suspected AMI, symptom presentation varies not only 363 364 by sex, but also by race; for example, Black women are more likely to present with GI distress, while White women are more likely to present with typical chest pain.²¹ Noting these differences 365 in symptom presentation is significant, as an atypical presentation with acute-onset GI distress 366 367 can modify the differential to include a diagnosis of GERD or peptic ulcer disease, which would 368 subsequently contribute to poorer outcomes, especially in Black women.

369

370 Limitations

371 There were a few limitations that were present in this study. The diagnosis of CS was based on

- 372 ICD-CM codes used for billing purposes, which are susceptible to erroneous coding. However,
- 373 previous studies comparing ICD diagnosis of CS to physician adjudication in hospital systems
- that validate these codes have demonstrated that ICD-CM codes are reliably coded and can
- accurately predict mortality in the context of MI and CS.^{22,23} Also, the NIS database recorded
- time in units of days as opposed to hours, so more exact timing information was not available.
- 377 Data included information on hospitalizations as opposed to patient-level data, which opens the
- possibility of repeat patients in the sample. Additionally, specific data such as vital signs,
- aboratory, and echocardiogram data were not available. Finally, there was a lack of information
- 380 on post-discharge outcomes, which could have provided further insight into post-intervention
- **381** results from the management of CS.

382

383 Conclusions

Our study found that, despite stark differences in access to early intervention for CS between men and women, in-hospital mortality did not differ significantly between sexes when treated equally within 24 hours of admission. Early intervention plays a role in mitigating sex-based differences in CS outcomes and should be prioritized in the management of CS. Future research

- 388 should focus on recognizing the atypical presentations of CS in women, identifying signs and
- 389 symptoms earlier in the disease course, and validating our findings in other cohorts.
- 390
- 391
- 392
- 393 394
- 395
- 396
- 397
- 398

399 References

- Daoulah A, Alshehri M, Panduranga P, et al. Clinical outcomes of patients with cardiogenic shock complicating acute myocardial infarction: The Gulf-Cardiogenic Shock (G-CS) Registry. Shock. 2024 Aug 12. doi:10.1097/SHK.00000000002433.
 Epub ahead of print. PMID: 39158570.
- 404
 405
 2. Aissaoui N, Puymirat E, Delmas C, et al. Trends in cardiogenic shock complicating acute myocardial infarction. Eur J Heart Fail. 2020;22(4):664-672. doi:10.1002/ejhf.1750.
- 406 3. Bertaina M, Morici N, Frea S, et al. Differences between cardiogenic shock related to acute decompensated heart failure and acute myocardial infarction. ESC Heart Fail.
 408 2023;10(6):3472-3482. doi:10.1002/ehf2.14510.
- 409
 4. Chioncel O, Parissis J, Mebazaa A, et al. Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22(8):1315-1341. doi:10.1002/ejhf.1922.
- Luna P, Kim LK, Yeo I, et al. Sex disparities in the management, outcomes, and transfer of patients hospitalized for cardiogenic shock. J Soc Cardiovasc Angiogr Interv.
 2023;3(3Part A):101212. doi:10.1016/j.jscai.2023.101212. PMID: 39131782; PMCID: PMC11307867.
- 417 6. Takla A, Mostafa MR, Eid MM, et al. Sex difference in outcomes and management of 418 cardiogenic shock: A systematic review and meta-analysis. Curr Probl Cardiol. 419 2024;49(11):102777. doi:10.1016/j.cpcardiol.2024.102777. Epub ahead of print. PMID: 420 39103132.
- 421 7. Abdallah N, Mohamoud A, Almasri T, et al. Relationships between sex and in-hospital outcomes of patients with acute cardiogenic shock receiving mechanical circulatory
 423 support. Cardiovasc Revasc Med. 2024 Jul 20:S1553-8389(24)00594-3.
 424 doi:10.1016/j.carrev.2024.07.017. Epub ahead of print. PMID: 39054172.
- 425
 8. Elgendy IY, Wegermann ZK, Li S, et al. Sex differences in management and outcomes of acute myocardial infarction patients presenting with cardiogenic shock. JACC Cardiovasc Interv. 2022;15(6):642-652. doi:10.1016/j.jcin.2021.12.033. PMID: 35331456.
- 428
 429
 429
 429
 429
 420
 420
 420
 420
 420
 421
 421
 421
 422
 422
 423
 424
 424
 424
 425
 426
 427
 428
 428
 429
 429
 429
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
 420
- 431 10. Shirakabe A, Matsushita M, Shibata Y, et al. Organ dysfunction, injury, and failure in cardiogenic shock. J Intensive Care. 2023;11(1):26. doi:10.1186/s40560-023-00676-1.
 433 PMID: 37386552; PMCID: PMC10308671.
- 434 11. Fisher T, Hill N, Kalakoutas A, et al. Sex differences in treatments and outcomes of
 435 patients with cardiogenic shock: a systematic review and epidemiological meta-analysis.
 436 Crit Care. 2024;28(1):192. doi:10.1186/s13054-024-04973-5.
- 437 12. Møller JE, Engstrøm T, Jensen LO, et al. Microaxial flow pump or standard care in infarct-related cardiogenic shock. N Engl J Med. 2024;390(15):1382-1393.
- 439 13. Yan I, et al. Sex differences in patients with cardiogenic shock. ESC Heart Fail.
 440 2021;8(3):1775-1783. doi:10.1002/ehf2.13303.
- 441 14. HCUP National Readmission Database (NRD). Healthcare Cost and Utilization Project
 442 (HCUP). Agency for Healthcare Research and Quality. Accessed October 09, 2021.
 443 https://www.hcup-us.ahrq.gov/nrdoverview.jsp
- 444 15. Ya'qoub L, Lemor A, Dabbagh M, et al. Racial, ethnic, and sex disparities in patients

445	with STEMI and cardiogenic shock. J Am Coll Cardiol Intv. 2021;14(6):653-660.
446	doi:10.1016/j.jcin.2021.01.003.
447	16. Stehli J, Dinh D, Dagan M, et al. Sex differences in prehospital delays in patients with
448	ST-segment-elevation myocardial infarction undergoing percutaneous coronary
449	intervention. JAHA. 2021;10(13):e019938. doi:10.1161/JAHA.120.019938.
450	17. Azazy A, Farid WA, Ibrahim WA, El Shafey WEH. Survival benefit of IABP in pre-
451	versus post-primary percutaneous coronary intervention in patients with cardiogenic
452	shock. Egypt Heart J. 2024;76(1):99. doi:10.1186/s43044-024-00527-w. PMID:
453	39107654; PMCID: PMC11303647.
454	18. Brodie BR, Stuckey TD, Muncy DB, et al. Importance of time-to-reperfusion in patients
455	with acute myocardial infarction with and without cardiogenic shock treated with primary
456	percutaneous coronary intervention. Am Heart J. 2003;145(4):708-715.
457	doi:10.1067/mhj.2003.9. PMID: 12679769.
458	19. Kaul P, et al. Temporal trends in patient and treatment delay among men and women
459	presenting with ST-elevation myocardial infarction. Am Heart J. 2011;161(1):91-97.
460	doi:10.1016/j.ahj.2010.09.016.
461	20. Lansky AJ, et al. Gender differences in outcomes after primary angioplasty versus
462	primary stenting with and without abciximab for acute myocardial infarction: results of
463	the Controlled Abciximab and Device Investigation to Lower Late Angioplasty
464	Complications (CADILLAC) trial. Circulation. 2005;111(13):1611-1618.
465	doi:10.1161/01.CIR.0000160362.55803.40.
466	21. Eastwood J, et al. Anginal symptoms, coronary artery disease, and adverse outcomes in
467	Black and White women: the NHLBI-sponsored Women's Ischemia Syndrome
468	Evaluation (WISE) study. J Womens Health. 2013;22(9):724-732.
469	doi:10.1089/jwh.2012.4031.
470	22. Lambert L, et al. Evaluation of care and surveillance of cardiovascular disease: can we
471	trust medico-administrative hospital data? Can J Cardiol. 2012;28(2):162-168.
472	doi:10.1016/j.cjca.2011.10.005.
473	23. Lauridsen MD, Gammelager H, Schmidt M, et al. Positive predictive value of
474	International Classification of Diseases, 10th revision, diagnosis codes for cardiogenic,
475	hypovolemic, and septic shock in the Danish National Patient Registry. BMC Med Res
170	

476 Methodol. 2015;15:23. doi:10.1186/s12874-015-0013-2.

Table 1. Baseline characteristics of patients stratified by CS type and sex (weighted).										
		Non-AMI-C		AMI-CS						
		31,655 (60.0	<i>.</i>		20,705 (40.0	·				
	Male	Female	p-value	Male	Female	p-value				
	390,505	241,150	< 0.001	267,810	152,895	< 0.001				
	(61.8)	(38.2)		(63.7)	(36.3)					
Demographics										
Age Group	1			1	1					
18-44	39,125	24,930	< 0.001	11,845	5,795	< 0.001				
	(10.0)	(10.3)		(4.4)	(3.8)					
45-64	141,780	72,050		96,105	41,370					
	(36.3)	(29.9)		(35.9)	(27.0)					
65-84	182,565	116,715		137,165	82,500					
	(46.8)	(47.4)		(51.2)	(53.9)					
85+	27,035	27,455		22,695	23,230					
	(6.9)	(11.4)		(8.5)	(15.2)					
Race/Ethnicity	1									
White	246,835	147,395	< 0.001	183,020	103,525	< 0.001				
	(65.6)	(63.4)		(71.4)	(70.4)					
Black	69,525	50,275		25,015	19,365					
	(18.5)	(21.6)		(9.7)	(13.2)					
Hispanic	34,005	19,785		25,700	13,000					
	(9.0)	(8.5)		(10.0)	(8.8)					
Asian	11,365	7,065		10,675	5,080					
	(3.0)	(3.0)		(4.2)	(3.5)					
Native	2,570	1,505		1,715	1,170					
American	(0.7)	(0.6)		(0.7)	(0.8)					
Other	11,785	6,585		10,215	4,875					
	(3.1)	(2.8)		(4.0)	(3.3)					
Quartile of Median H					1					
<25 th	116,585	76,505	< 0.001	76,210	47,690	< 0.001				
	(30.5)	(32.3)		(29.0)	(31.7)					
$26^{\text{th}} - 50^{\text{th}}$	99,445	61,950		70,715	40,985					
	(26.0)	(26.1)		(27.0)	(27.3)					
$51^{th} - 75^{th}$	90,070	54,665		63,025	34,420					
	(23.6)	(23.0)		(24.0)	(22.9)					
$76^{\text{th}} - 100^{\text{th}}$	76,250	44,125		52,075	27,325					
	(19.9)	(18.6)		(19.9)	(18.2)					
Insurance										
Medicare	223,675	155,185	< 0.001	154,770	106,735	< 0.001				
	(57.4)	(64.4)		(57.9)	(69.9)					
Medicaid	55,630	31,890		28,365	14,545					
	(14.3)	(13.2)		(10.6)	(9.5)					
Private	82,505	43,480		60,715	24,240					
	(21.2)	(18.0)		(22.7)	(15.9)					
Self-Pay	13,670	5,905		12,610	4,630					

Table 1. Baseline characteristics of patients stratified by CS type and sex (weighted).

				(47)	(2,0)	
	(3.5)	(2.5)		(4.7)	(3.0)	
No Charge	695	365		810	305	
	(0.2)	(0.2)		(0.3)	(0.2)	
Other	13,805	4,040		10,105	2,275	
	(3.5)	(1.7)		(3.8)	(1.5)	
Hospital Type	1-0-00	a a ta z	0.010			0.001
Government	47,950	28,495	0.013	26,165	14,035	< 0.001
	(12.3)	(11.8)		(9.8)	(9.2)	
Private, Non-	301,035	185,990		200,540	116,325	
Profit	(77.0)	(77.1)		(74.9)	(76.0)	
Private, For-	41,520	26,665		41,105	22,535	
Profit	(10.6)	(11.0)		(15.4)	(14.7)	
Hospital Teaching Sta				I	I	
Rural	13,175	9,290	< 0.001	12,140	8,195	< 0.001
	(3.4)	(3.9)		(4.5)	(5.4)	
Urban, Non-	52,265	34,915		46,230	26,635	
Teaching	(13.4)	(14.5)		(17.3)	(17.4)	
Urban,	325,065	196,945		209,440	118,065	
Teaching	(83.2)	(81.7)		(78.2)	(77.2)	
Comorbidities & Pri				1	1	
Obesity	68,960	49,945	< 0.001	42,130	27,410	< 0.001
	(17.7)	(20.7)		(15.7)	(17.9)	
Dyslipidemia	162,685	91,920	< 0.001	136,680	75,520	< 0.001
	(41.7)	(38.1)		(51.0)	(49.4)	
Diabetes Mellitus	149,720	88,565	< 0.001	112,160	67,555	< 0.001
	(38.3)	(36.7)		(41.9)	(44.2)	
Chronic	296,000	175,060	< 0.001	199,995	117,175	< 0.001
Hypertension	(75.8)	(72.6)		(74.7)	(76.6)	
Tobacco Use	48,555	22,225	< 0.001	46,430	21,345	< 0.001
	(12.4)	(9.2)		(17.3)	(14.0)	
Peripheral Vascular	21,535	11,165	< 0.001	19,510	11,575	0.137
Disease	(5.5)	(4.6)		(7.3)	(7.6)	
Chronic Heart	156,605	96,585	0.859	95,455	57,405	< 0.001
Failure	(40.1)	(40.0)		(35.6)	(37.6)	
Chronic Kidney	175,165	90,745	< 0.001	89,720	49,225	< 0.001
Disease	(44.9)	(37.6)		(33.5)	(32.2)	
Chronic Liver	101,045	56,175	< 0.001	61,715	31,420	< 0.001
Disease	(25.9)	(23.3)		(23.0)	(20.6)	
Valvular Heart	100,290	69,700	< 0.001	46,935	32,640	< 0.001
Disease	(25.7)	(28.9)		(17.5)	(21.4)	
Coronary Artery	195,860	86,305	< 0.001	202,640	103,145	< 0.001
Disease	(50.2)	(35.8)		(75.7)	(67.5)	
Stroke	13,035	8,715	0.007	11,500	7,470	< 0.001
	(3.3)	(3.6)		(4.3)	(4.9)	
Prior PCI	38,505	14,760	< 0.001	34,094	15,360	< 0.001
	(9.9)	(6.1)		(12.7)	(10.0)	

Prior CABG	39,770	12,175	< 0.001	24,925	9,785	< 0.001
	(10.2)	(5.0)		(9.3)	(6.4)	

Results presented as n (%). Comparisons made using pearson's χ^2 test. Comparisons made using pearson's χ^2 test for categorical variables and Mann-Whitney test for continuous variables. All analyses are survey weight adjusted. Abbreviations: AMI-CS, acute myocardial infarction cardiogenic shock; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting.

Table 2. Frequency of procedural and clinical outcomes stratified by sex and CS type.

	1 -	lon-AMI-CS		AMI-CS				
	63	31,655 (60.02	2)	42	20,705 (39.98	3)		
	Male	Female	p-value	Male	Female	p-value		
	390,505	241,150	< 0.001	267,810	152,895	< 0.001		
	(61.8)	(38.2)		(63.7)	(36.3)			
Procedural Outcomes		_		-	-			
Revascularization	39,770	15,395	< 0.001	140,215	67,770	< 0.001		
	(10.2)	(6.4)		(52.4)	(44.3)			
PCI	9,385	4,555	< 0.001	104,185	53,160	< 0.001		
	(2.4)	(1.9)		(38.9)	(34.8)			
CABG	32,110	11,570	< 0.001	47,465	18,735	< 0.001		
	(8.2)	(4.8)		(17.7)	(12.3)			
MCS	49,290	21,795	< 0.001	96,320	41,710	< 0.001		
	(12.6)	(9.0)		(36.0)	(27.3)			
IABP	27,615	11,745	< 0.001	65,870	29,565	< 0.001		
	(7.1)	(4.9)		(24.6)	(19.3)			
pLVAD	18,655	6,875	< 0.001	32,750	13,050	< 0.001		
	(4.8)	(2.5)		(12.2)	(8.5)			
ECMO	11,300	6,445	0.026	7,885	2,635	< 0.001		
	(2.9)	(2.7)		(2.9)	(1.7)			
RHC	82,485	40,015	< 0.001	51,600	25,800	< 0.001		
	(21.1)	(16.6)		(19.3)	(16.9)			
Advanced Heart Failure	17,100	5,590	< 0.001	1,580	510	< 0.001		
Therapy	(4.4)	(2.3)		(0.6)	(0.3)			
LVAD	10,630	3,100	< 0.001	1,300	380	< 0.001		
	(2.7)	(1.3)		(0.5)	(0.3)			
Heart Transplant	6,595	2,530	< 0.001	310	130	0.151		
_	(1.7)	(1.0)		(0.1)	(0.1)			
Clinical Outcomes								
In-hospital Mortality	118,205	85,360	< 0.001	90,940	58,355	< 0.001		
	(30.3)	(35.4)		(34.0)	(38.2)			
Invasive Mechanical	106,950	74,690	< 0.001	89,655	52,860	0.001		
Ventilation	(27.4)	(31.0)		(33.5)	(34.6)			
Major Bleeding	81,895	48,495	< 0.001	53,865	29,420	0.003		
	(21.0)	(20.1)		(20.1)	(19.2)			
Acute Kidney Injury	265,625	149,005	< 0.001	163,645	85,090	< 0.001		
	(68.0)	(61.8)		(61.1)	(55.7)			
Acute Kidney Injury	31,800	17,715	< 0.001	18,270	8.755	< 0.001		

Requiring Dialysis	(8.1)	(7.4)		(6.8)	(5.7)	
Stroke	985	1,025	< 0.001	645	605	< 0.001
	(0.3)	(0.4)		(0.2)	(0.4)	
Total Hospitalization Cost	268,220.4	233,424.5	< 0.001	254,776.1	216,624.1	< 0.001
in USD (mean, standard	(4,607.4)	(3,528.7)		(2,762.1)	(2,376.2)	
error)						
Length of Stay in days	12.65	11.82	< 0.001	9.99	9.32	< 0.001
(mean, standard error)	(0.10)	(0.10)		(0.06)	(0.07)	

Results presented as (%), unless otherwise noted. Comparisons made using pearson's χ^2 test for categorical variables. All analyses are survey weight adjusted.

Abbreviations: AMI-CS, acute myocardial infarction cardiogenic shock; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MCS, mechanical support device; IABP, intra-aortic balloon pump; pLVAD, percutaneous left ventricular support device; ECMO, extracorporeal membrane oxygenation; RHC, right heart catheterization; LVAD, left ventricular assist device.

Table 3. Odds ratios of clinical outcomes in women versus men with AMI-CS based on first intervention type received.

Outcomes in Women	Unadjusted Odds	p-value	Model 1 (Only	p-	Model 2 (All	p-value
compared to Men	Ratio	-	Demographics)	value	Baseline	-
			Odds Ratio		Characteristics)	
					Odds Ratio	
Revascularization						
In-hospital Mortality	1.23 (1.18-1.29)	< 0.001	1.13 (1.08-1.19)	< 0.001	1.15 (1.09-1.22)	< 0.001
IMV	1.06 (1.01-1.10)	0.011	1.06 (1.01-1.10)	0.013	1.07 (1.02-1.12)	0.003
Major Bleeding	1.02 (0.97-1.07)	0.322	1.02 (0.98-1.08)	0.245	0.98 (0.94-1.04)	0.689
AKI	0.79 (0.76-0.83)	< 0.001	0.73 (0.70-0.76)	< 0.001	0.71 (0.67-0.74)	< 0.001
AKI Requiring Dialysis	0.89 (0.81-0.98)	0.021	0.87 (0.79-0.97)	0.013	0.86 (0.77-0.96)	0.007
Stroke	1.78 (1.25-3.52)	0.001	1.67 (1.16-2.40)	0.006	1.62 (1.12-2.35)	0.010
MCS						
In-hospital Mortality	1.19 (1.13-1.26)	< 0.001	1.12 (1.06-1.19)	< 0.001	1.15 (1.08-1.22)	< 0.001
IMV	1.11 (1.05-1.17)	< 0.001	1.10 (1.04-1.17)	0.001	1.12 (1.06-1.19)	< 0.001
Major Bleeding	1.10 (1.04-1.17)	0.001	1.11 (1.04-1.18)	0.001	1.08 (1.01-1.15)	0.015
AKI	0.78 (0.74-0.82)	< 0.001	0.74 (0.70-0.78)	< 0.001	0.72 (0.68-0.76)	< 0.001
AKI Requiring Dialysis	0.85 (0.77-0.94)	0.003	0.84 (0.76-0.94)	0.002	0.83 (0.74-0.93)	0.002
Stroke	1.52 (0.92-2.50)	0.104	1.46 (0.87-2.45)	0.153	1.33 (0.77-2.29)	0.309
RHC						
In-hospital Mortality	1.12 (1.04-1.20)	0.001	1.06 (0.99-1.15)	0.085	1.10 (1.02-1.19)	0.008
IMV	1.09 (1.02-1.18)	0.008	1.11 (1.04-1.20)	0.003	1.12 (1.04-1.21)	0.002
Major Bleeding	1.03 (0.96-1.11)	0.357	1.05 (0.98-1.14)	0.158	1.03 (0.95-1.12)	0.378
AKI	0.71 (0.66-0.76)	< 0.001	0.68 (0.63-0.73)	< 0.001	0.69 (0.64-0.75)	< 0.001
AKI Requiring Dialysis	0.76 (0.67-0.86)	< 0.001	0.73 (0.64-0.83)	< 0.001	0.76 (0.66-0.87)	< 0.001
Stroke	1.12 (0.63-1.99)	0.687	1.06 (0.59-1.90)	0.837	0.96 (0.52-1.77)	0.901
Advanced Heart Failure	e Therapy					
In-hospital Mortality	1.13 (0.58-2.20)	0.705	1.12 (0.48-2.59)	0.790	1.37 (0.54-3.50)	0.503
IMV	1.17 (0.63-2.15)	0.618	1.11 (0.55-2.25)	0.751	1.16 (0.58-2.34)	0.667
Major Bleeding	1.26 (0.77-2.08)	0.352	1.64 (0.91-2.96)	0.096	1.59 (0.87-2.89)	0.126

AKI	0.77 (0.44-1.35)	0.363	0.85 (0.48-1.51)	0.579	0.81 (0.41-1.58)	0.525
AKI Requiring Dialysis	1.21 (0.57-2.58)	0.616	1.53 (0.61-3.87)	0.360	1.76 (0.58-5.33)	0.317
Stroke	1.55 (0.14-17.6)	0.721	9.66 (0.52-179)	0.124	N/A	N/A

All analyses involve multivariate logistic regression and are survey weight adjusted. Model 1 includes adjustment with year of NIS data, age group, race, household income quartile, insurance status, hospital type and teaching status. Model 2 includes adjustment with all model 1 covariates as well as past medical history of diabetes mellitus, hypertension, dyslipidemia, tobacco use, obesity, chronic kidney disease, liver disease, peripheral vascular disease, coronary artery disease, chronic heart failure, valvular heart disease, stroke, prior PCI, and prior CABG. Abbreviations: AMI-CS, acute myocardial infarction cardiogenic shock; MCS, mechanical support device; RHC, right heart catheterization; IMV, invasive mechanical ventilation; AKI, acute kidney injury.

Table 4. Odds ratios of clinical outcomes in women versus men with Non-AMI-CS based on first intervention type received.

Outcomes in Women	Unadjusted Odds	p-value	Model 1 (Only	p-value	Model 2 (All	p-value
compared to Men	Ratio		Demographics)		Baseline	
			Odds Ratio		Characteristics)	
					Odds Ratio	
Revascularization				T		
In-hospital Mortality	1.43 (1.28-1.59)	< 0.001	1.37 (1.22-1.54)	< 0.001	1.38 (1.23-1.56)	< 0.001
IMV	1.11 (1.00-1.23)	0.033	1.10 (0.99-1.23)	0.060	1.11 (1.00-1.24)	0.050
Major Bleeding	1.11 (1.02-1.21)	0.011	1.16 (1.06-1.27)	0.001	1.09 (0.99-1.19)	0.068
AKI	0.86 (0.79-0.94)	0.001	0.86 (0.78-0.94)	0.001	0.82 (0.74-0.90)	< 0.001
AKI Requiring Dialysis	1.01 (0.85-1.21)	0.856	0.99 (0.82-1.19)	0.924	0.95 (0.78-1.16)	0.638
Stroke	1.29 (0.67-2.48)	0.439	1.42 (0.71-2.86)	0.318	1.32 (0.66-2.65)	0.423
MCS	-					
In-hospital Mortality	1.30 (1.20-1.40)	< 0.001	1.30 (1.20-1.42)	< 0.001	1.31 (1.21-1.43)	< 0.001
IMV	1.27 (1.17-1.37)	< 0.001	1.27 (1.17-1.39)	< 0.001	1.28 (1.18-1.40)	< 0.001
Major Bleeding	1.12 (1.05-1.20)	0.001	1.14 (1.06-1.23)	< 0.001	1.10 (1.02-1.18)	0.012
AKI	0.68 (0.63-0.73)	< 0.001	0.67 (0.62-0.73)	< 0.001	0.66 (0.60-0.73)	< 0.001
AKI Requiring Dialysis	0.91 (0.82-1.02)	0.114	0.91 (0.81-1.02)	0.126	0.94 (0.82-1.06)	0.324
Stroke	1.64 (0.96-2.83)	0.070	1.69 (0.96-2.98)	0.068	1.64 (0.93-2.89)	0.089
RHC	_					-
In-hospital Mortality	1.30 (1.21-1.39)	< 0.001	1.31 (1.22-1.41)	< 0.001	1.32 (1.22-1.43)	< 0.001
IMV	1.30 (1.21-1.39)	< 0.001	1.31 (1.22-1.41)	< 0.001	1.27 (1.17-1.36)	< 0.001
Major Bleeding	1.01 (0.95-1.08)	0.609	1.02 (0.96-1.09)	0.427	0.98 (0.91-1.04)	0.507
AKI	0.69 (0.65-0.73)	< 0.001	0.68 (0.64-0.72)	< 0.001	0.73 (0.68-0.77)	< 0.001
AKI Requiring Dialysis	0.95 (0.86-1.04)	0.285	0.95 (0.85-1.04)	0.273	1.00 (0.90-1.11)	0.970
Stroke	1.45 (0.89-2.37)	0.127	1.54 (0.93-2.56)	0.090	1.55 (0.91-2.63)	0.104
Advanced Heart Failure	Therapy					
In-hospital Mortality	1.05 (0.81-1.36)	0.671	1.13 (0.86-1.50)	0.361	1.20 (0.88-1.63)	0.242
IMV	1.00 (0.81-1.23)	0.952	0.99 (0.79-1.24)	0.969	1.05 (0.84-1.31)	0.635
Major Bleeding	1.03 (0.88-1.20)	0.665	0.99 (0.84-1.16)	0.906	1.02 (0.87-1.20)	0.768
AKI	0.62 (0.52-0.72)	< 0.001	0.61 (0.52-0.71)	< 0.001	0.68 (0.57-0.81)	< 0.001
AKI Requiring Dialysis	0.79 (0.59-1.05)	0.115	0.76 (0.57-1.03)	0.081	0.79 (0.57-1.09)	0.157
Stroke	1.45 (0.65-3.20)	0.354	1.39 (0.60-3.22)	0.432	1.44 (0.62-3.35)	0.393

All analyses involve multivariate logistic regression and are survey weight adjusted. Model 1 includes adjustment with year of NIS data, age group, race, household income quartile, insurance status, hospital type and teaching

status. Model 2 includes adjustment with all model 1 covariates as well as past medical history of diabetes mellitus, hypertension, dyslipidemia, tobacco use, obesity, chronic kidney disease, liver disease, peripheral vascular disease, coronary artery disease, chronic heart failure, valvular heart disease, stroke, prior PCI, and prior CABG. Abbreviations: AMI-CS, acute myocardial infarction cardiogenic shock; MCS, mechanical support device; RHC, right heart catheterization; IMV, invasive mechanical ventilation; AKI, acute kidney injury.

Table 5. Odds ratios of in-hospital mortality in women receiving early (within 24 hours) versu	us
late or no intervention by CS type.	

In-hospital Mortality	Unadjusted	p-value	Model 1 (Only	p-value	Model 2 (All	p-value
in Women Receiving	Odds Ratio	-	Demographics)	1	Baseline	-
Early Intervention			Odds Ratio		Characteristics) Odds	
compared to Women					Ratio	
Not Receiving Early						
Intervention						
AMI-CS						
Revascularization	0.65 (0.61-0.69)	< 0.001	0.66 (0.62-0.70)	< 0.001	0.77 (0.72-0.82)	< 0.001
PCI	0.66 (0.63-0.71)	< 0.001	0.68 (0.64-0.72)	< 0.001	0.79 (0.74-0.85)	< 0.001
CABG	0.63 (0.55-0.73)	< 0.001	0.63 (0.55-0.74)	< 0.001	0.69 (0.59-0.82)	< 0.001
MCS	0.87 (0.82-0.93)	< 0.001	0.94 (0.88-1.00)	0.068	1.06 (0.99-1.14)	0.073
IABP	0.69 (0.64-0.75)	< 0.001	0.72 (0.67-0.78)	< 0.001	0.83 (0.77-0.91)	< 0.001
pLVAD	1.50 (1.35-1.68)	< 0.001	1.67 (1.49-1.88)	< 0.001	1.78 (1.58-2.01)	< 0.001
ECMO	1.71 (1.32-2.2)	< 0.001	2.38 (1.83-3.10)	< 0.001	2.15 (1.62-2.85)	< 0.001
RHC	0.87 (0.79-0.96)	0.005	0.90 (0.819-0.99)	0.048	0.979 (0.88-1.08)	0.688
Non-AMI-CS						
Revascularization	0.42 (0.37-0.49)	< 0.001	0.42 (0.36-0.49)	< 0.001	0.57 (0.49-0.67)	< 0.001
PCI	0.76 (0.60-0.95)	0.017	0.70 (0.55-0.88)	0.003	0.87 (0.68-1.12)	0.296
CABG	0.32 (0.27-0.39)	< 0.001	0.33 (0.28-0.40)	< 0.001	0.46 (0.38-0.56)	< 0.001
MCS	0.92 (0.82-1.01)	0.109	0.97 (0.87-1.09)	0.663	1.05 (0.94-1.18)	0.360
IABP	0.64 (0.54-0.74)	< 0.001	0.65 (0.55-0.77)	< 0.001	0.78 (0.67-0.93)	0.005
pLVAD	1.41 (1.14-1.74)	0.001	1.48 (1.19-1.84)	< 0.001	1.56 (1.24-1.96)	< 0.001
ECMO	1.31 (1.10-1.57)	0.002	1.52 (1.26-1.82)	< 0.001	1.40 (1.15-1.69)	0.001
RHC	0.42 (0.37-0.46)	< 0.001	0.45 (0.39-0.50)	< 0.001	0.50 (0.44-0.57)	< 0.001

All analyses involve multivariate logistic regression and are survey weight adjusted. Model 1 includes adjustment with year of NIS data, age group, race, household income quartile, insurance status, hospital type and teaching status. Model 2 includes adjustment with all model 1 covariates as well as past medical history of diabetes mellitus, hypertension, dyslipidemia, tobacco use, obesity, chronic kidney disease, liver disease, peripheral vascular disease, coronary artery disease, chronic heart failure, valvular heart disease, stroke, prior PCI, and prior CABG. Abbreviations: AMI-CS, acute myocardial infarction cardiogenic shock; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MCS, mechanical support device; IABP, intra-aortic balloon pump; pLVAD, percutaneous left ventricular support device; ECMO, extracorporeal membrane oxygenation; RHC, right heart catheterization; LVAD, left ventricular assist device.

Figure 1. Frequency of early intervention within 24 hours stratified by sex and CS type.

Unadjusted results. Figure 1A and 1B shows results for non-AMI-CS and AMI-CS, respectively.

Abbreviations: AMI-CS, acute myocardial infarction cardiogenic shock; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MCS, mechanical support device; IABP, intra-aortic balloon pump; pLVAD, percutaneous left ventricular support device; ECMO, extracorporeal membrane oxygenation; RHC, right heart catheterization; LVAD, left ventricular assist device.




Figure 2. Adjusted odds ratios of receiving early intervention within 24 hours of admission stratified by CS type.

All analyses involve multivariate logistic regression and are survey weight adjusted. Odds ratios reported are adjusted for year of NIS data, age group, race, household income quartile, insurance status, hospital type and teaching status as well as past medical history of diabetes mellitus, hypertension, dyslipidemia, tobacco use, obesity, chronic kidney disease, liver disease, peripheral vascular disease, coronary artery disease, chronic heart failure, valvular heart disease, stroke, prior PCI, and prior CABG.

Note: advanced heart failure therapies data not reported due to low counts preventing proper construction of logistic regression.

Abbreviations: AMI-CS, acute myocardial infarction cardiogenic shock; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MCS, mechanical support device; IABP, intra-aortic balloon pump; pLVAD, percutaneous left ventricular support device; ECMO, extracorporeal membrane oxygenation; RHC, right heart catheterization.




Figure 3. Adjusted odds ratios of in-hospital mortality following early intervention within 24 hours of admission stratified by CS type.

All analyses involve multivariate logistic regression and are survey weight adjusted. Each regression is performed on a dataset filtered to only include CS patients who received a particular intervention within 24 hours. Odds ratios reported are adjusted for year of NIS data, age group, race, household income quartile, insurance status, hospital type and teaching status as well as past medical history of diabetes mellitus, hypertension, dyslipidemia, tobacco use, obesity, chronic kidney disease, liver disease, peripheral vascular disease, coronary artery disease, chronic heart failure, valvular heart disease, stroke, prior PCI, and prior CABG.

Note: advanced heart failure therapies data not reported due to low counts preventing proper construction of logistic regression.

Abbreviations: AMI-CS, acute myocardial infarction cardiogenic shock; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MCS, mechanical support device; IABP, intra-aortic balloon pump; pLVAD, percutaneous left ventricular support device; ECMO, extracorporeal membrane oxygenation; RHC, right heart catheterization.

